Table: monthly_update_prescription_drug_wac_inc , manufacturer_name like R*

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  *

oshpd_id manufacturer_name date_reported ndc_number drug_product_description wac_effective_date wac_increase_amount wac_after_increase patent_expiration_date drug_source_type unit_sales_volume_in_us unit_sales_volume_non_public_indicator gross_sales_us_dollars gross_sales_us_dollars_non_public_indicator cost_increase_factors cost_increase_factors_non_public_indicator change_improvement_description change_improvement_non_public_indicator acquisition_date company_acquired_from acquisition_price acquisition_price_non_public_indicator acquisition_price_comment wac_at_acquisition wac_year_prior_to_acquisition year_drug_introduced_to_market wac_at_intro_to_market supporting_documents general_comments
Rx0000356 Radius Health, Inc. 01/31/2025 70539000102 TYMLOS 80 MCG Pen / Carton Injection: 3120 mcg/1.56 mL (2000 mcg/mL) in a single-patient-use prefilled pen. The prefilled pen delivers 30 daily doses of 80 mcg abaloparatide in 40 mcL of sterile, clear, colorless solution. 01/01/2025 160.02 2827.02 01/10/2040 Single Source Drug None None None 1 None 1 The price increase was not necessitated by a change or improvement in the drug. None None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Radius believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 10/26/2023. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Radius Health, Inc. did not acquire this product from another manufacturer within the previous five years. As a result, Radius Health has left columns N-U blank because they are not applicable to this product.
Rx0000356 Radius Health, Inc. 01/31/2025 70539000101 TYMLOS 80 MCG Pen. Injection: 3120 mcg/1.56 mL (2000 mcg/mL) in a single-patient-use prefilled pen. The prefilled pen delivers 30 daily doses of 80 mcg abaloparatide in 40 mcL of sterile, clear, colorless solution. 01/01/2025 160.02 2827.02 01/10/2040 Single Source Drug None None None 1 None 1 The price increase was not necessitated by a change or improvement in the drug. None None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Radius believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 10/26/2023. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Radius Health, Inc. did not acquire this product from another manufacturer within the previous five years. As a result, Radius Health has left columns N-U blank because they are not applicable to this product.
Rx0000363 Recordati Rare Diseases, inc. 04/15/2025 55292041005 Cystadrops Ophthalmic Solution 0.37 % 1 5ml bottle 01/01/2025 115.46 2424.65 None Single Source Drug None None None 1 None 1 None 1 None None None None None None None None None None None
Rx0000363 Recordati Rare Diseases, inc. 04/15/2025 55292032060 Isturisa Oral Tablet 1 MG 60 tablets 01/01/2025 944.10 10881.98 10/12/2035 Single Source Drug None None None 1 None 1 None 1 None None None None None None None None None None None
Rx0000363 Recordati Rare Diseases, inc. 04/15/2025 55292032160 Isturisa Oral Tablet 5 MG 60 tablets 01/01/2025 4720.49 54409.87 10/12/2035 Single Source Drug None None None 1 None 1 None 1 None None None None None None None None None None None
Rx0000363 Recordati Rare Diseases, inc. 04/15/2025 55292070255 Panhematin Intravenous Solution Reconstituted 350 MG 1 vial 01/01/2025 245.97 10940.49 None Single Source Drug None None None 1 None 1 None 1 None None None None None None None None None None None
Rx0000363 Recordati Rare Diseases, inc. 04/15/2025 55292013901 Signifor LAR Intramuscular Suspension Reconstituted ER 10 MG 1 vial 01/01/2025 953.38 20021.07 05/23/2028 Single Source Drug None None None 1 None 1 None 1 None None None None None None None None None None None
Rx0000363 Recordati Rare Diseases, inc. 04/15/2025 55292014001 Signifor LAR Intramuscular Suspension Reconstituted ER 20 MG 1 vial 01/01/2025 953.38 20021.07 05/23/2028 Single Source Drug None None None 1 None 1 None 1 None None None None None None None None None None None
Rx0000363 Recordati Rare Diseases, inc. 04/15/2025 55292014101 Signifor LAR Intramuscular Suspension Reconstituted ER 30 MG 1 vial 01/01/2025 953.38 20021.07 05/23/2028 Single Source Drug None None None 1 None 1 None 1 None None None None None None None None None None None
Rx0000363 Recordati Rare Diseases, inc. 04/15/2025 55292014201 Signifor LAR Intramuscular Suspension Reconstituted ER 40 MG 1 vial 01/01/2025 953.38 20021.07 05/23/2028 Single Source Drug None None None 1 None 1 None 1 None None None None None None None None None None None
Rx0000363 Recordati Rare Diseases, inc. 04/15/2025 55292014301 Signifor LAR Intramuscular Suspension Reconstituted ER 60 MG 1 vial 01/01/2025 953.38 20021.07 05/23/2028 Single Source Drug None None None 1 None 1 None 1 None None None None None None None None None None None
Rx0000363 Recordati Rare Diseases, inc. 04/15/2025 55292013160 Signifor Subcutaneous Solution 0.3 MG/ML 60 Ampules 01/01/2025 1004.34 21091.07 12/14/2026 Single Source Drug None None None 1 None 1 None 1 None None None None None None None None None None None
Rx0000363 Recordati Rare Diseases, inc. 04/15/2025 55292013260 Signifor Subcutaneous Solution 0.6 MG/ML 60 Ampules 01/01/2025 1004.34 21091.07 12/14/2026 Single Source Drug None None None 1 None 1 None 1 None None None None None None None None None None None
Rx0000363 Recordati Rare Diseases, inc. 04/15/2025 55292013360 Signifor Subcutaneous Solution 0.9 MG/ML 60 Ampules 01/01/2025 1004.34 21091.07 12/14/2026 Single Source Drug None None None 1 None 1 None 1 None None None None None None None None None None None
Rx0000166 Redhill Biopharma, Inc. 04/17/2025 57841115002 Talicia Oral Capsule Delayed Release 250-12.5-10 MG 2 Bottles of 84 Capsules 01/01/2025 24.34 835.73 02/12/2034 Single Source Drug None None None 1 None 1 None 1 None None None None None None None None None None None
Rx0000239 Rigel Pharmaceuticals, Inc. 03/31/2025 71332000660 GAVRETO 100MG 60 CAPS 01/03/2025 667.42 11812.00 11/01/2036 Single Source Drug None None None 1 Pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, commercial and government rebates, patient support, overall research and development costs None This WAC increase is not necessitated by a change or improvement in the prescription drug. None 02/22/2024 BluePrint Medicines Corporation 15000000 None None 11144.58 10613.89 2020 9621.60 None None
Rx0000239 Rigel Pharmaceuticals, Inc. 03/31/2025 71332000690 GAVRETO 100MG 90 CAPS 01/03/2025 1001.15 17718.00 11/01/2036 Single Source Drug None None None 1 Pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, commercial and government rebates, patient support, overall research and development costs None This WAC increase is not necessitated by a change or improvement in the prescription drug. None 02/22/2024 BluePrint Medicines Corporation 15000000 None None 16716.85 15920.81 2020 14432.40 None None
Rx0000239 Rigel Pharmaceuticals, Inc. 03/31/2025 71332000101 TAVALISSE TAB 100MG 60 TABS 01/03/2025 730.00 15530.00 07/27/2032 Single Source Drug None None None 1 Pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, commercial and government rebates, patient support, overall research and development costs None This WAC increase is not necessitated by a change or improvement in the prescription drug. None None None None None None None None None None None None
Rx0000239 Rigel Pharmaceuticals, Inc. 03/31/2025 71332000201 TAVALISSE Tab 150MG 60 TABS 01/03/2025 730.00 15530.00 07/27/2032 Single Source Drug None None None 1 Pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, commercial and government rebates, patient support, overall research and development costs None This WAC increase is not necessitated by a change or improvement in the prescription drug. None None None None None None None None None None None None